NCT01677897

Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients

Impact of the Addition of Metformin to Abiraterone in Pre-docetaxel Metastatic Castration-resistant Prostate Cancer Patients Progressing on Abiraterone Treatment (MetAb-Pro): a Phase II Pilot Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Kantonsspital Graubünden · Academic / Other
• Sex: Male
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the impact of the addition of metformin to abiraterone on survival in patients with metastatic prostate cancer

Detailed description

The purpose of this study is to assess the impact of the addition of metformin to abiraterone on survival in patients with metastatic chemotherapy-naive prostate cancer

Conditions

• Metastatic Prostate Cancer

Interventions

Type	Name	Description
DRUG	Metformin	Adding Metformin to Abiraterone in case of PSA-Progression

Timeline

• Start date: 2013-08-01
• Primary completion: 2017-12-01
• Completion: 2018-06-01
• First posted: 2012-09-03
• Last updated: 2019-03-05

Locations

1 site across 1 country: Switzerland